Parnell Pharmaceuticals Holdings Ltd
PARN
PARN was delisted on the 30th of December, 2016.
2 hedge funds and large institutions have $143K invested in Parnell Pharmaceuticals Holdings Ltd in 2017 Q2 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
21% less capital invested
Capital invested by funds: $181K → $143K (-$38K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$28.2K |
PARN Hedge Fund Activity: Q2 2017 in Review
2 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Parnell Pharmaceuticals Holdings Ltd (PARN) for Q2 2017, worth a combined $143K — down 21% from $181K a quarter earlier.
Fund positioning in PARN was balanced in Q2 2017: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was Sabby Management, cutting an estimated $28.2K.
- 2 institutional investors held Parnell Pharmaceuticals Holdings Ltd (PARN) as of Q2 2017, unchanged from Q1 2017.
- Funds reported $143K of Parnell Pharmaceuticals Holdings Ltd stock for Q2 2017, down 21% quarter-over-quarter.
- 0 funds opened new Parnell Pharmaceuticals Holdings Ltd positions in Q2 2017 and 0 closed out.
- The largest Parnell Pharmaceuticals Holdings Ltd seller in Q2 2017 was Sabby Management, an estimated $28.2K sold.
Based on aggregated 13F filings for Q2 2017.